



Product Information and Testing

Cell Line: BG02

Lot: 13-Dec-04

Table of Contents

STR Report	2
Mycoplasma Report	3
Karyotype Report	6

If you have any questions please contact WiCell's technical support staff at www.wicell.org and we will be happy to assist you.

Thank you,

WiCell

Short Tandem Repeat Analysis*

Sample Report: 9641-STR
BG02 (batch- 13 Dec 04)

UW HLA#: 58210

Sample Date: 03/10/08
Received Date: 03/10/08

Requestor: WiCell Research Institute

Test Date: 03/16/08

File Name: 080317

Report Date: 03/21/08

Sample Name: (label on tube)
9641-STR**Description:** DNA Extracted by WiCell

440ug/mL; 260/280 = 1.90

Locus	Repeat #	STR Genotype
D16S539	5, 8-15	12,12
D7S820	6-14	12,14
D13S317	7-15	11,11
D5S818	7-15	11,12
CSF1PO	6-15	8,10
TPOX	6-13	11,11
Amelogenin	NA	X,Y
TH01	5-11	8,9
vWA	11, 13-21	18,19

Comments: Based on the 9641-STR DNA submitted by WI Cell dated 03/10/08 and received on 03/10/08, this sample (UW HLA# 58210) matches exactly the STR profile of the human stem cell line **BG02** comprising 13 allelic polymorphisms across the 8 STR loci analyzed. No STR polymorphisms other than those corresponding to the human BG02 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/ noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the DNA sample submitted corresponds to the BG02 stem cell line and it was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%. A copy of this report was issued via electronic mail to WI Cell Research Institute on Sunday, March 23, 2008.

HLA/Molecular Diagnostics Laboratory

HLA/Molecular Diagnostics Laboratory

* Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.



APPENDIX I

Document #: DCF3008A
Edition #: 06
Effective date: 9/17/2003
Title: DNA FLUOROCHROME ASSAY RESULTS

DNA-FLUOROCHROME ASSAY RESULTS

Procedures 3008, 3009, 3011

Sample ID # 51758 M-250 Date Rec'd: 02/19/2008 P.O. # RP1695

Indicator Cells Inoculated: Date/Initials: 2/21/08 / JA

Fixation: Date/Initials: 2/25/08 / JA

Staining: Date/Initials: 2/25/08 / JA

TEST/CONTROL ARTICLE:

BG02-DDL-2 (13Dec04)

LOT# NA

Wicell QA

WiCell Research Institute

Phone:

Fax #:

DNA FLUOROCHROME ASSAY RESULTS:

X **NEGATIVE:** A reaction with staining limited to the nuclear region, which indicates no mycoplasmal contamination.

 POSITIVE: A significant amount of extranuclear staining which strongly suggests mycoplasmal contamination.

 INCONCLUSIVE:

 A significant amount of extranuclear staining consistent with low - level mycoplasmal contamination or nuclear degeneration.

 A significant amount of extranuclear staining consistent with bacterial, fungal or other microbial contaminant or viral CPE. Morphology not consistent for mycoplasmal contamination.

COMMENTS:

Date: 2/25/08 Results Read by: JA Date of Review: 2/25/08 Reviewed by: CM



BIONIQUE TESTING LABORATORIES, INC.
156 FAY BROOK DRIVE
SARANAC LAKE, NY 12983
PHONE: 518-891-2356 FAX: 518-891-5753

APPENDIX IV

Page 1 of 2

Document#: DCF3013D
Edition#: 10
Effective Date: 07/15/2003
Title: M-250 FINAL REPORT SHEET

M-250 FINAL REPORT

Direct Specimen Culture
Procedure 3008, 3011, 3013

TO: Wicell QA
WiCell Research Institute

120

18

BTL SAMPLE ID#: 51758 P.O.#: RP1695 DATE REC'D: 02/19/2008

TEST/CONTROL ARTICLE:

BG02-DDL-2 (13Dec04)

LOT#: NA

DIRECT CULTURE SET-UP (DAY 0)

DATE: 02/20/2008

INDICATOR CELL LINE (VERO)

SEE DNA FLUOROCHROME RECORD SHEET

DATE

THIOGLYCOLLATE BROTH

DAY 7 + ☒ 02/27/2008

DAY 28 + ☒ 03/19/2008

BROTH-FORTIFIED COMMERCIAL

0.5 mL SAMPLE DAY 7 + ☒ 02/27/2008

6.0 mL BROTH DAY 28 + ☒ 03/19/2008

BROTH-MODIFIED HAYFLICK

0.5 mL SAMPLE DAY 7 + ☒ 02/27/2008

6.0 mL BROTH DAY 28 + ☒ 03/19/2008

BROTH-HEART INFUSION

0.5 mL SAMPLE DAY 7 + ☒ 02/27/2008

6.0 mL BROTH DAY 28 + ☒ 03/19/2008


(See Reverse)

Document#: DCF3013D
 Edition#: 10
 Effective Date: 07/15/2003
 Title: M-250 FINAL REPORT SHEET

SAMPLE ID#:	51758	AEROBIC	MICROAEROPHILIC	DATE
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7	+	⊖	02/27/2008
	DAY 14	+	⊖	03/05/2008
	DAY 21	+	⊖	03/12/2008
AGAR PLATES-MODIFIED HAYFLICK	DAY 7	+	⊖	02/27/2008
	DAY 14	+	⊖	03/05/2008
	DAY 21	+	⊖	03/12/2008
AGAR PLATES-HEART INFUSION	DAY 7	+	⊖	02/27/2008
	DAY 14	+	⊖	03/05/2008
	DAY 21	+	⊖	03/12/2008
BROTH SUBCULTURES (DAY 7)		DATE: 02/27/2008		
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7	+	⊖	03/05/2008
	DAY 14	+	⊖	03/12/2008
	DAY 21	+	⊖	03/19/2008
AGAR PLATES-MODIFIED HAYFLICK	DAY 7	+	⊖	03/05/2008
	DAY 14	+	⊖	03/12/2008
	DAY 21	+	⊖	03/19/2008
AGAR PLATES-HEART INFUSION	DAY 7	+	⊖	03/05/2008
	DAY 14	+	⊖	03/12/2008
	DAY 21	+	⊖	03/19/2008

RESULTS: No detectable mycoplasmal contamination

3/19/08
 Date


 Director Technical Services
 Carolyn Kay Lincoln, Ph.D.

M-250 Procedural Summary: The objective of this test is to ascertain whether or not detectable mycoplasmas are present in an *in vitro* cell culture sample, be it a primary culture, hybridoma, master seed stock or cell line. This procedure combines an indirect DNA staining approach to detect non-cultivable mycoplasmas with a direct culture methodology utilizing three different mycoplasmal media formulations. The indirect approach involves the inoculation of the sample into a mycoplasma-free VERO (ATCC) indicator cell line and performing a DNA fluorochrome assay after 72-120 hours of incubation. The direct culture aspect of the test utilizes three different mycoplasmal media including both broth and agar formulations. The sample is inoculated into each of the 3 broth formulations and also onto duplicate plates (0.1 mL/plate) for each of the 3 agar formulations. Subculture from broth to fresh agar plates is carried out after 7 days incubation. Agar plates are incubated aerobically and microaerophilically in order to detect any colony forming units morphologically indicative of mycoplasmal contamination. Issuance of the final report with signature of the Scientific Director/Study Director signifies that the required controls were performed concurrently with the test sample(s) as detailed in the referenced SOPs and that all test conditions have been found to meet the required acceptance criteria for a valid test, including the appropriate results for the positive and negative controls.

Report Date: March 07, 2008

Case Details:

Cell Line: BG02 (NSCB 9641) (batch 13 Dec 04 p20)

Passage #: 27

Date Completed: 3/6/2008

Cell Line Gender: male

Investigator: National Stem Cell Bank

Specimen: hESC on MEF feeder

Date of Sample: 2/26/2008


Tests, Reason for: Distribution lot testing (Depositor Lot)

Results: 46,XY

Completed by CS, CLSp(CG), on 3/6/2008

Reviewed and interpreted by KDM, PhD, FACMG, on 3/6/2008

Interpretation: No abnormalities were detected at the stated band level of resolution.



Cell: S01-02

Slide: B

Slide Type: Karyotyping

Cell Results: Karyotype: 46,XY

of Cells Counted: 20

of Cells Karyotyped: 6

of Cells Analyzed: 8

Band Level: 425-500

Results Transmitted by Fax / Email / Post
Sent By: _____

Date: _____
Sent To: _____